{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28"],"submitter":["Coudert B"],"pubmed_abstract":["<h4>Background</h4>The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bevacizumab for PET-predicted poor-responders improved pathological complete response (pCR) rates (43.8% vs 24.0%). We investigated long-term study outcomes.<h4>Methods</h4>Patients were treated in three groups. All patients initially received two cycles of standard neoadjuvant therapy with [¹⁸F]-FDG PET conducted before each cycle. Those with ≥70% change in the maximum standardised uptake value (∆SUVmax) received four further cycles of standard neoadjuvant therapy (PET responders). PET-predicted poor-responders (∆SUVmax <70%) were randomis"],"journal":["EClinicalMedicine"],"pagination":["100566"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7649610"],"repository":["biostudies-literature"],"pubmed_title":["Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study."],"pmcid":["PMC7649610"],"pubmed_authors":["Coudert B","Dupin J","Du FL","Chauvet MP","Arnould L","Coeffic D","Berriolo-Riedinger A","Barbe C","Prevost JB","Ferrero JM","Paintaud G","Gabelle P","Dupre PF","Kerrou K","Pierga JY","Mouret-Reynier MA","Bachelot T","Thibault G","Petit T","Ferhat A"],"additional_accession":[]},"is_claimable":false,"name":"Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.","description":"<h4>Background</h4>The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bevacizumab for PET-predicted poor-responders improved pathological complete response (pCR) rates (43.8% vs 24.0%). We investigated long-term study outcomes.<h4>Methods</h4>Patients were treated in three groups. All patients initially received two cycles of standard neoadjuvant therapy with [¹⁸F]-FDG PET conducted before each cycle. Those with ≥70% change in the maximum standardised uptake value (∆SUVmax) received four further cycles of standard neoadjuvant therapy (PET responders). PET-predicted poor-responders (∆SUVmax <70%) were randomis","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2026-05-04T03:45:58.24Z","creation":"2020-11-22T09:48:06Z"},"accession":"S-EPMC7649610","cross_references":{"pubmed":["33205032"],"doi":["10.1016/j.eclinm.2020.100566"]}}